SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin receives favorable ruling for generic Yaz Oral Contraceptive Tablets

17 Apr 2013 Evaluate

Pharma major, Lupin has declared that the US Court of Appeals for the Federal Circuit has ruled in its favor regarding its appeal of a previous judgment by a lower court for Bayer AG’s Yaz oral contraceptive product.

On April 16, 2013 the United States Court of Appeals for the Federal Circuit has ruled that United States Patent No RE 37,564 (the RE '564 Patent) is invalid thereby reversing the district court’s decision of validity.

Lupin’s Generic Drospirenone and Ethinyl Estradiol Tablets (3 mg + 0.02 mg) of Bayer AG’s Yaz tablets are indicated for prevention of pregnancy, to treat the symptoms of premenstrual dysphoric disorder (PMDD) for women and to treat moderate acne for women at least 14 years old only if the patient desires an oral contraceptive for birth control. The total sales for Branded and generic sales for the product stood at $361 million (IMS MAT Dec 2012).

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

Lupin Share Price

2419.10 -30.70 (-1.25%)
30-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 2000.75
Dr. Reddys Labs. 1144.35
Cipla 1466.00
Lupin 2419.10
Zydus Lifesciences 1115.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: